A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Kumar, K M Prasanna; Ghosh, Sujoy; Canovatchel, William; Garodia, Nishant; Rajashekar, Sujith Tumkur

doi:10.4103/2230-8210.196016

Cited by 11 publications

(10 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms of action of SGLT2i and their effect on various physiological parameters are depicted in Fig. 1 [ 13 , 25 ].…”

Section: Sglt2i and Diabetesmentioning

confidence: 99%

“… Mechanisms of action of SGLT2i and their effect on the physiological system in the human body [ 13 , 25 ]. BP blood pressure, CV cardiovascular, HDL-C high-density lipoprotein cholesterol, HOMA homeostatic model assessment, LDL-C low-density lipoprotein cholesterol, IR insulin resistance, IS insulin sensitivity, SGLT sodium glucose co-transporter, T2DM type 2 diabetes mellitus, ↑ increase, ↓ decrease.…”

Section: Sglt2i and Diabetesmentioning

confidence: 99%

“…Hypoglycaemia is a major cause of concern with some antidiabetic agents; however, pertaining to their insulin-independent mechanism of action, SGLT2i produce less hypoglycaemia than other antidiabetic agents [ 13 , 25 ]. Nonetheless, when SGLT2i are used concomitantly with insulin or insulin secretagogues, the risk of hypoglycaemia increases, and close monitoring of the patient is required [ 143 ].…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

See 2 more Smart Citations

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Singh

Unnikrishnan²,

Zargar³

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

The current diabetes management strategies not only aim at controlling glycaemic parameters but also necessitate continuous medical care along with multifactorial risk reduction through a comprehensive management concept. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of evolving antidiabetic agents that have the potential to play a pivotal role in the comprehensive management of patients with diabetes due to their diverse beneficial effects. SGLT2i provide moderate glycaemic control, considerable body weight and blood pressure reduction, and thus have the ability to lower the risk of macrovascular and microvascular complications. Some of the unique characteristics associated with SGLT2i, such as reduction in body weight (more visceral fat mass loss than subcutaneous fat loss), reduction in insulin resistance and improvement in β-cell function, as measured by homeostatic model assessment-β (HOMA-β) could be potentially beneficial and help in overcoming some of the challenges faced by Indian patients with diabetes. In addition, a patient-centric approach with individualised treatment during SGLT2i therapy is inevitable in order to reduce diabetic complications and improve quality of life. Despite their broad benefits profile, the risk of genital tract infections, volume depletion, amputations and diabetic ketoacidosis associated with SGLT2i should be carefully monitored. In this compendium, we systematically reviewed the literature from Medline, Cochrane Library, and other relevant databases and attempted to provide evidence-based recommendations for the positioning of SGLT2i in the management of diabetes in the Indian population. Funding : AstraZeneca Pharma India Limited.

show abstract

“…The mechanisms of action of SGLT2i and their effect on various physiological parameters are depicted in Fig. 1 [ 13 , 25 ].…”

Section: Sglt2i and Diabetesmentioning

confidence: 99%

Section: Sglt2i and Diabetesmentioning

confidence: 99%

Section: Safety and Tolerabilitymentioning

confidence: 99%

See 1 more Smart Citation

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Singh

Unnikrishnan²,

Zargar³

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…The risk of hypoglycemia is minimal with SGLT2is. [25262739] These extraordinary features of this new class have attracted attention of endocrinologists as well as cardiologists, and has earned the status of first line OHAs in leading guidelines. Hence, more and more diabetic patients are being prescribed these drugs.…”

Section: Implications For Clinical Practicementioning

confidence: 99%

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure

Pradhan

Vohra

Vishwakarma

et al. 2019

J Family Med Prim Care

View full text Add to dashboard Cite

SGLT-2 inhibitors are a novel class of anti-diabetic agents which act by inhibiting glucose reabsorption in proximal convoluted tubules of kidney. Apart from maintaining glucose homeostasis they exert a number of positive effects on the cardiovascular system like weight loss, decreasing blood pressure, preserving renal function, reducing triglycerides, natriuresis and improving endothelial dysfunction. In large clinical trials, all the three prototype agents – Empaglifozin, Canaglifozin and dapaglifozin have shown reductions in major adverse cardiovascular events including cardiovascular deaths, non fatal MI, stroke and heart failure (HF) hospitalizations. The reduction in heart failure hospitalization is a surprising finding and trials of these drug are now underway for HF also. More surprising is the fact that the benefits are comparable or even better that achieved by recently approved novel drugs for HF. In this review, we briefly discuss the pathophysiology of HF in diabetes, describe the prototype SGLT-2 molecules available, their data from large cardiovascular outcome trials till date and their role in current practice of diabetes management.

show abstract

“…T2DM is characterized by the inability of pancreatic β-cells to produce enough insulin resulting hyperglycemia and the inability of insulin to bind with its receptors restrict the absorption of glucose (insulin resistance) into the cells [ 2 , 3 ]. Disease prevalence is increasing for sure due to unknown causes and the lack of therapeutic strategies [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Polyvalent therapeutic vaccine for type 2 diabetes mellitus: Immunoinformatics approach to study co-stimulation of cytokines and GLUT1 receptors

Muhammad

Ashfaq

Zafar

et al. 2020

BMC Mol and Cell Biol

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus (T2DM) is a worldwide disease that have an impact on individuals of all ages causing micro and macro vascular impairments due to hyperglycemic internal environment. For ultimate treatment to cure T2DM, association of diabetes with immune components provides a strong basis for immunotherapies and vaccines developments that could stimulate the immune cells to minimize the insulin resistance and initiate gluconeogenesis through an insulin independent route. Methodology: Immunoinformatics based approach was used to design a polyvalent vaccine for T2DM that involved data accession, antigenicity analysis, T-cell epitopes prediction, conservation and proteasomal evaluation, functional annotation, interactomic and in silico binding affinity analysis. Results: We found the binding affinity of antigenic peptides with major histocompatibility complex (MHC) Class-I molecules for immune activation to control T2DM. We found 13-epitopes of 9 amino acid residues for multiple alleles of MHC class-I bears significant binding affinity. The downstream signaling resulted by T-cell activation is directly regulated by the molecular weight, amino acid properties and affinity of these epitopes. Each epitope has important percentile rank with significant ANN IC 50 values. These high score potential epitopes were linked using AAY, EAAAK linkers and HBHA adjuvant to generate T-cell polyvalent vaccine with a molecular weight of 35.6 kDa containing 322 amino acids residues. In silico analysis of polyvalent construct showed the significant binding affinity (− 15.34 Kcal/mol) with MHC Class-I. This interaction would help to understand our hypothesis, potential activation of T-cells and stimulatory factor of cytokines and GLUT1 receptors. Conclusion: Our system-level immunoinformatics approach is suitable for designing potential polyvalent therapeutic vaccine candidates for T2DM by reducing hyperglycemia and enhancing metabolic activities through the immune system.

show abstract

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Cited by 11 publications

References 101 publications

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure

Polyvalent therapeutic vaccine for type 2 diabetes mellitus: Immunoinformatics approach to study co-stimulation of cytokines and GLUT1 receptors

Contact Info

Product

Resources

About